Drugs / M7437
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07360314 | Feb 2026 → Sep 2028 expected | cancer | EMD Serono Research & Development Institute, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M7437 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07360314 ↗ |
| Route | Intravenous | “Participants will receive M7437 as an intravenous infusion” NCT07360314 ↗ |
| Target | LY6E | “Anti-Ly6E Exatecan Antibody-Drug Conjugate M7437” NCT07360314 ↗ |